<SEC-DOCUMENT>0001104659-25-115071.txt : 20251121
<SEC-HEADER>0001104659-25-115071.hdr.sgml : 20251121
<ACCEPTANCE-DATETIME>20251121181311
ACCESSION NUMBER:		0001104659-25-115071
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251120
FILED AS OF DATE:		20251121
DATE AS OF CHANGE:		20251121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Kemble George
		CENTRAL INDEX KEY:			0001858176
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41742
		FILM NUMBER:		251509228

	MAIL ADDRESS:	
		STREET 1:		SAGIMET BIOSCIENCES INC.
		STREET 2:		155 BOVET RD., STE. 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sagimet Biosciences Inc.
		CENTRAL INDEX KEY:			0001400118
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205991472
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		155 BOVET RD., SUITE 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402
		BUSINESS PHONE:		(650) 561-8600

	MAIL ADDRESS:	
		STREET 1:		155 BOVET RD., SUITE 303
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	3-V Biosciences, Inc.
		DATE OF NAME CHANGE:	20070521
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2531988-1_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-11-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001400118</issuerCik>
        <issuerName>Sagimet Biosciences Inc.</issuerName>
        <issuerTradingSymbol>SGMT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001858176</rptOwnerCik>
            <rptOwnerName>Kemble George</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>SAGIMET BIOSCIENCES INC.</rptOwnerStreet1>
            <rptOwnerStreet2>155 BOVET RD., SUITE 303</rptOwnerStreet2>
            <rptOwnerCity>SAN MATEO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94402</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Executive Chairman</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Series A Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-20</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>37688</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>7.6942</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>81005</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Elizabeth Rozek, Attorney-in-Fact</signatureName>
        <signatureDate>2025-11-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
